Biomarker Research in Ovarian Cancer

Video

In Partnership With:

Leigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.

Leigha Senter, MS, LGC, licensed genetic counselor and clinical associate professor of Human Genetics in the Department of Internal Medicine at The Ohio State University Wexner Medical Center, discusses ongoing biomarker research efforts in ovarian cancer.

The search for effective biomarkers that might predict response to treatment in patients with ovarian cancer continues, says Senter. Despite many research efforts that have already been made, investigators are just scratching the surface of all there is to learn about biomarkers in this space.

It is known that not all BRCA mutations will behave the same way in cells. Likewise, genes that work in the same pathway may not behave in the same way either. As such, molecular studies are vital to ovarian cancer research, explains Senter.

The challenge is that the way that different clinical trials define biomarkers can vary. Furthermore, many options are now available. The ultimate goal is to determine what the molecular signature is in order to choose an appropriate corresponding therapy, according to Senter. To achieve such a goal, more progress needs to be made, concludes Senter.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,